ClinicalTrials.gg
CompletedNCT01262638Updated Mar 17, 2021Results posted

A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

A Phase 2 interventional study of ETC-1002 and Placebo in Dyslipidemia, sponsored by Esperion Therapeutics, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-17.

Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 349 studies in Dyslipidemias with a site in United States — 23 open to participants now, 34 under way, 6 of them phase 3. Dyslipidemias · United States.

Enrollment
124th of 316
177 · median 105
Started
2010
with 17 others
Phase 2
66 of 349
2 open now
Registered
143rd of 349
by date

Among the 349 studies in Dyslipidemias with a site in United States, this one is the 124th largest by enrollment of the 316 interventional ones that give a count, is one of 18 that started in 2010, is one of 66 in phase 2, and was the 143rd registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

23 of the 349 studies in Dyslipidemias with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 349 studies in Dyslipidemias with a site in United States, or all of them as a file.
02

Study summary

This Phase 2 proof-of-concept study will assess the lipid regulating efficacy and safety of ETC-1002 in subjects with hypercholesterolemia and either normal or elevated triglycerides.

03

Conditions studied

  • Dyslipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  • Provision of written prior to any study-specific procedure
  • Fasting LDL-C between 130 and 220 mg/dL following wash-out of all lipid regulating medications and supplements
  • Fasting triglyceride \<400 mg/dL following wash-out of all lipid regulating medications and supplements
  • between 18 and 35 mg/kg2

Major Exclusion Criteria:

  • cardiovascular disease, diabetes or uncontrolled hypertension
  • Females of child bearing potential (i.e., females who are not surgically sterile or )
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
177 participants (actual)

Study arms

  • Experimental
    ETC-1002 120 mg (Group 1)

    Subjects with hypercholesterolemia and normal triglycerides

    Drug: ETC-1002

  • Experimental
    ETC-1002 80 mg (Group 2)

    Subjects with hypercholesterolemia and normal triglycerides

    Drug: ETC-1002

  • Experimental
    ETC-1002 40 mg (Group 3)

    Subjects with hypercholesterolemia and normal triglycerides

    Drug: ETC-1002

  • Experimental
    Placebo (Group 4)

    Subjects with hypercholesterolemia and normal triglycerides

    Drug: Placebo

  • Experimental
    ETC-1002 120 mg (Group 5)

    Subjects with hypercholesterolemia and elevated triglycerides

    Drug: ETC-1002

  • Experimental
    ETC-1002 80 mg (Group 6)

    Subjects with hypercholesterolemia and elevated triglycerides

    Drug: ETC-1002

  • Experimental
    ETC-1002 40 mg (Group 7)

    Subjects with hypercholesterolemia and elevated triglycerides

    Drug: ETC-1002

  • Experimental
    Placebo (Group 8)

    Subjects with hypercholesterolemia and elevated triglycerides

    Drug: Placebo

Interventions

  • ETC-1002 daily for 12 weeks

  • DrugPlacebo

    Placebo daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 12 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C)

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. Least square (LS) mean percent change from Baseline to Week 12 was based on an analysis of covariance (ANCOVA) model with effects of treatment and triglyceride (TG) stratum and Baseline value as a covariate. Missing LDL-C values at Week 12 were imputed using the last observation carried forward (LOCF) procedure (only post-Baseline values were carried forward).

    Time frame: Baseline; 12 weeks

  2. Percent Change From Baseline to Week 12 in LDL-C by Triglyceride (TG) Stratum

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and center and Baseline value as a covariate. Missing LDL-C values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

    Time frame: Baseline; 12 weeks

Secondary outcomes

  1. Percent Change From Baseline to Week 12 in TG

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing TG values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

    Time frame: Baseline; 12 weeks

  2. Percent Change From Baseline to Week 12 in High-Density Lipoprotein-Cholesterol (HDL-C)

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing HDL-C values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

    Time frame: Baseline; 12 weeks

  3. Percent Change From Baseline to Week 12 in Non-HDL-C

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing non-HDL-C values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

    Time frame: Baseline; 12 weeks

  4. Percent Change From Baseline to Week 12 in Total Cholesterol (TC)

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing TC values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

    Time frame: Baseline; 12 weeks

  5. Percent Change From Baseline to Week 12 in Apolipoprotein B (ApoB)

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing ApoB values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

    Time frame: Baseline; 12 weeks

  6. Percent Change From Baseline to Week 12 in Apolipoprotein AI (ApoAI)

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing ApoAI values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

    Time frame: Baseline; 12 weeks

  7. Percent Change From Baseline to Week 12 in Lipoprotein (a)

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing Lipoprotein (a) values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

    Time frame: Baseline; 12 weeks

  8. Percent Change From Baseline to Week 12 in Free Fatty Acids (FFA)

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing FFA values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

    Time frame: Baseline; 12 weeks

  9. Percent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (hsCRP)

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the value from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing hsCRP values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

    Time frame: Baseline; 12 weeks

  10. Percent Change From Baseline to Week 12 in Total LDL Particles

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

    Time frame: Baseline; 12 weeks

  11. Percent Change From Baseline to Week 12 in Total HDL Particles

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

    Time frame: Baseline; 12 weeks

  12. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs were defined as adverse events (AEs) that began or worsened in severity after the first dose of study medication, occurring up to 30 days after the last dose of study medication.

    Time frame: up to 12 weeks

  13. Number of Participants With Clinically Significant Physical Examination Findings

    Clinical significance was determined by the investigator.

    Time frame: up to 12 weeks

  14. Number of Participants With Clinically Important Changes From Baseline in Vital Sign Values

    Clinical importance was determined by the investigator.

    Time frame: Baseline; up to 12 weeks

  15. Number of Participants With Clinically Important Changes From Baseline in Electrocardiogram Values

    Clinical importance was determined by the investigator.

    Time frame: Baseline; up to 12 weeks

  16. Number of Participants With the Indicated Abnormal Laboratory Parameter Values at Week 12

    Laboratory abnormalities are laboratory values that are outside the normal range.

    Time frame: Week 12

07

Results

Posted Mar 16, 2021

Participant flow

A total of 177 participants were enrolled and treated across 11 study sites in the United States.

Participant flow — Overall Study
MilestoneETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Started45444444
Completed38383837
Not completed7667
Withdrew: Adverse event3434
Withdrew: Protocol violation1001
Withdrew: Withdrawal by subject2101
Withdrew: Per investigator/sponsor/regulatory body0010
Withdrew: Lost to follow-up1111
Withdrew: Participant went out of town0010

Outcome measures

PrimaryPercent Change From Baseline to Week 12 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C)

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. Least square (LS) mean percent change from Baseline to Week 12 was based on an analysis of covariance (ANCOVA) model with effects of treatment and triglyceride (TG) stratum and Baseline value as a covariate. Missing LDL-C values at Week 12 were imputed using the last observation carried forward (LOCF) procedure (only post-Baseline values were carried forward).

Time frame:
Baseline; 12 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 12 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C)
Percent ChangeETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Percent Change From Baseline to Week 12 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C)-17.9 ± 2.17-25.0 ± 2.12-26.6 ± 2.16-2.1 ± 2.16
Statistical analysis
  • ETC-1002 40 mg vs Placebo · ANCOVA · p = <0.0001 · Difference in least squares means: -15.7 · 95% CI -21.8 to -9.7
  • ETC-1002 80 mg vs Placebo · ANCOVA · p = <0.0001 · Difference in least squares means: -22.9 · 95% CI -28.9 to -16.9
  • ETC-1002 120 mg vs Placebo · ANCOVA · p = <0.0001 · Difference in least squares means: -24.5 · 95% CI -30.5 to -18.4
PrimaryPercent Change From Baseline to Week 12 in LDL-C by Triglyceride (TG) Stratum

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and center and Baseline value as a covariate. Missing LDL-C values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

Time frame:
Baseline; 12 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 12 in LDL-C by Triglyceride (TG) Stratum
Percent ChangeETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Normal (TG<150 mg/dL)-17.8 ± 2.92-21.9 ± 2.73-29.2 ± 2.720.3 ± 2.89
Elevated (TG≥150 mg/dL)-17.8 ± 3.21-28.1 ± 3.22-23.6 ± 3.37-4.5 ± 3.22
SecondaryPercent Change From Baseline to Week 12 in TG

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing TG values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

Time frame:
Baseline; 12 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 12 in TG
Percent ChangeETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Percent Change From Baseline to Week 12 in TG-15.1 ± 4.29-10.6 ± 4.161.1 ± 4.26-1.2 ± 4.29
SecondaryPercent Change From Baseline to Week 12 in High-Density Lipoprotein-Cholesterol (HDL-C)

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing HDL-C values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

Time frame:
Baseline; 12 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 12 in High-Density Lipoprotein-Cholesterol (HDL-C)
Percent ChangeETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Percent Change From Baseline to Week 12 in High-Density Lipoprotein-Cholesterol (HDL-C)7.2 ± 2.220.9 ± 2.124.4 ± 2.162.4 ± 2.18
SecondaryPercent Change From Baseline to Week 12 in Non-HDL-C

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing non-HDL-C values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

Time frame:
Baseline; 12 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 12 in Non-HDL-C
Percent ChangeETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Percent Change From Baseline to Week 12 in Non-HDL-C-17.4 ± 2.01-22.7 ± 1.95-23.0 ± 2.00-2.3 ± 2.00
SecondaryPercent Change From Baseline to Week 12 in Total Cholesterol (TC)

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Weeks -1 and 0. LS mean percent change from Baseline to Week 12 based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing TC values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

Time frame:
Baseline; 12 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 12 in Total Cholesterol (TC)
Percent ChangeETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Percent Change From Baseline to Week 12 in Total Cholesterol (TC)-11.5 ± 1.53-17.8 ± 1.50-17.1 ± 1.53-1.4 ± 1.53
SecondaryPercent Change From Baseline to Week 12 in Apolipoprotein B (ApoB)

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the value from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing ApoB values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

Time frame:
Baseline; 12 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 12 in Apolipoprotein B (ApoB)
Percent ChangeETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Percent Change From Baseline to Week 12 in Apolipoprotein B (ApoB)-14.6 ± 1.83-18.4 ± 1.82-22.1 ± 1.84-0.9 ± 1.83
SecondaryPercent Change From Baseline to Week 12 in Apolipoprotein AI (ApoAI)

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing ApoAI values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

Time frame:
Baseline; 12 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 12 in Apolipoprotein AI (ApoAI)
Percent ChangeETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Percent Change From Baseline to Week 12 in Apolipoprotein AI (ApoAI)2.9 ± 1.96-2.7 ± 1.950.0 ± 1.97-3.1 ± 1.95
SecondaryPercent Change From Baseline to Week 12 in Lipoprotein (a)

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing Lipoprotein (a) values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

Time frame:
Baseline; 12 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 12 in Lipoprotein (a)
Percent ChangeETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Percent Change From Baseline to Week 12 in Lipoprotein (a)0.3 ± 5.207.6 ± 5.2016.2 ± 5.27-2.7 ± 5.22
SecondaryPercent Change From Baseline to Week 12 in Free Fatty Acids (FFA)

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing FFA values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

Time frame:
Baseline; 12 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 12 in Free Fatty Acids (FFA)
Percent ChangeETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Percent Change From Baseline to Week 12 in Free Fatty Acids (FFA)2.5 ± 6.15-14.4 ± 6.085.3 ± 6.343.6 ± 6.09
SecondaryPercent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (hsCRP)

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the value from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing hsCRP values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

Time frame:
Baseline; 12 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (hsCRP)
Percent ChangeETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Percent Change From Baseline to Week 12 in High-Sensitivity C-Reactive Protein (hsCRP)18.4 ± 42.4557.0 ± 42.4448.0 ± 43.2486.6 ± 42.45
SecondaryPercent Change From Baseline to Week 12 in Total LDL Particles

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

Time frame:
Baseline; 12 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 12 in Total LDL Particles
Percent ChangeETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Percent Change From Baseline to Week 12 in Total LDL Particles-14.8 ± 2.26-16.3 ± 2.23-20.7 ± 2.341.9 ± 2.22
SecondaryPercent Change From Baseline to Week 12 in Total HDL Particles

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week 0. LS mean percent change from Baseline to Week 12 was based on an ANCOVA model with effects of treatment and TG stratum and Baseline value as a covariate. Missing values at Week 12 were imputed using the LOCF procedure (only post-Baseline values were carried forward).

Time frame:
Baseline; 12 weeks
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline to Week 12 in Total HDL Particles
Percent ChangeETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Percent Change From Baseline to Week 12 in Total HDL Particles5.7 ± 1.783.6 ± 1.747.3 ± 1.840.4 ± 1.75
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as adverse events (AEs) that began or worsened in severity after the first dose of study medication, occurring up to 30 days after the last dose of study medication.

Time frame:
up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Number of Participants With Treatment-emergent Adverse Events (TEAEs)34323133
SecondaryNumber of Participants With Clinically Significant Physical Examination Findings

Clinical significance was determined by the investigator.

Time frame:
up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Physical Examination Findings
ParticipantsETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Number of Participants With Clinically Significant Physical Examination Findings2202
SecondaryNumber of Participants With Clinically Important Changes From Baseline in Vital Sign Values

Clinical importance was determined by the investigator.

Time frame:
Baseline; up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Important Changes From Baseline in Vital Sign Values
ParticipantsETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Number of Participants With Clinically Important Changes From Baseline in Vital Sign Values0000
SecondaryNumber of Participants With Clinically Important Changes From Baseline in Electrocardiogram Values

Clinical importance was determined by the investigator.

Time frame:
Baseline; up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Important Changes From Baseline in Electrocardiogram Values
ParticipantsETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Number of Participants With Clinically Important Changes From Baseline in Electrocardiogram Values0000
SecondaryNumber of Participants With the Indicated Abnormal Laboratory Parameter Values at Week 12

Laboratory abnormalities are laboratory values that are outside the normal range.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With the Indicated Abnormal Laboratory Parameter Values at Week 12
ParticipantsETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Alanine aminotransferase4334
Aspartate aminotransferase5682
Creatine kinase12835
Creatinine1010
Total bilirubin1101
Uric acid6863
Hemoglobin5842
Leukocytes3211

Adverse events

Collected over up to 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ETC-1002 40 mg0/45 (0%)0/45 (0%)15/45 (33.3%)
ETC-1002 80 mg0/44 (0%)0/44 (0%)18/44 (40.9%)
ETC-1002 120 mg0/44 (0%)0/44 (0%)17/44 (38.6%)
Placebo0/44 (0%)1/44 (2.3%)17/44 (38.6%)
Most frequent serious events
Most frequent serious events
EventETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
Chest PainGeneral disorders0/450/440/441/44
Most frequent other events
Most frequent other events
EventETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlacebo
HeadacheNervous system disorders5/455/447/444/44
ArthralgiaMusculoskeletal and connective tissue disorders2/452/441/446/44
NauseaGastrointestinal disorders3/453/444/442/44
Pain in ExtremityMusculoskeletal and connective tissue disorders0/450/444/441/44
Urinary Tract InfectionInfections and infestations4/451/440/441/44
DiarrhoeaGastrointestinal disorders3/453/441/443/44
BronchitisInfections and infestations0/453/441/441/44
MyalgiaMusculoskeletal and connective tissue disorders2/452/443/440/44
CoughRespiratory, thoracic and mediastinal disorders2/453/441/441/44
FatigueGeneral disorders3/451/441/441/44

Baseline characteristics

Baseline data are reported for members of the Safety Population, comprised of all randomized participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(Years)ETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlaceboTotal
Mean58.4 ± 8.6658.8 ± 9.0056.7 ± 9.9255.5 ± 10.4057.3 ± 9.52
Sex: Female, Male
Sex: Female, Male(Participants)ETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlaceboTotal
Female2621191379
Male1923253198
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlaceboTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander01012
Black or African American772622
White38364137152
More than one race00101
Unknown or Not Reported00000
Calculated Low-density Lipoprotein Cholesterol (LDL-C)
Calculated Low-density Lipoprotein Cholesterol (LDL-C)(milligrams per deciliter (mg/dL))ETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlaceboTotal
Mean163.1 ± 24.88170.2 ± 26.23165.0 ± 23.08167.4 ± 22.03166.4 ± 24.05
LDL-C by Triglyceride (TG) Stratum
LDL-C by Triglyceride (TG) Stratum(mg/dL)ETC-1002 40 mgETC-1002 80 mgETC-1002 120 mgPlaceboTotal
Normal Stratum, TG<150 mg/dL153.8 ± 22.06164.6 ± 25.36160.2 ± 17.30166.6 ± 17.87161.2 ± 21.15
Elevated Stratum, TG≥150 mg/dL172.9 ± 24.35175.7 ± 26.46169.8 ± 27.25168.2 ± 25.94171.7 ± 25.73
08

Study locations

11 sites
  • Chandler, Arizona 85225, United States
  • Greenbrae, California 94904, United States
  • Santa Rosa, California 95405, United States
  • Jacksonville, Florida 32216, United States
  • Chicago, Illinois 60654, United States
  • Iowa City, Iowa 52242, United States
  • Louisville, Kentucky 40213, United States
  • Kalamazoo, Michigan 49007, United States
  • Raleigh, North Carolina 27609, United States
  • Houston, Texas 77030, United States
  • Richmond, Virginia 23294, United States
09

References and documents

Publications

  • Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, Margulies J, Newton RS. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24;62(13):1154-62. doi: 10.1016/j.jacc.2013.05.050. Epub 2013 Jun 13. PubMed 23770179 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2021, 9 years 6 months after primary completion. A results delay was requested in Aug 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2010
First posted
Dec 17, 2010
Start
Dec 2010
Primary completionActual
Aug 23, 2011
CompletionActual
Aug 23, 2011
Results delay requested
Aug 13, 2015
Results first posted
Mar 16, 2021
Last update
Mar 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01262638
Responsible party
Sponsor
First posted
Dec 17, 2010
Start date
Dec 2010
Primary completion
Aug 23, 2011
Completion
Aug 23, 2011
Results posted
Mar 16, 2021
Last update
Mar 17, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion